Beam Therapeutics [BEAM] vs Vertex [VRTX] Detailed Stock Comparison
Beam Therapeutics
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Beam Therapeutics wins in 5 metrics, Vertex wins in 12 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Beam Therapeutics | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -5.62 | 28.68 | Beam Therapeutics |
| Price-to-Book Ratio | 2.41 | 6.02 | Beam Therapeutics |
| Debt-to-Equity Ratio | 14.79 | 8.89 | Vertex |
| PEG Ratio | 0.57 | -0.22 | Vertex |
| EV/EBITDA | -3.62 | 20.53 | Beam Therapeutics |
| Profit Margin (TTM) | 0.00% | 31.86% | Vertex |
| Operating Margin (TTM) | -1,419.22% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -41.94% | 22.77% | Vertex |
| Return on Assets (TTM) | -21.02% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-356.19M | $-978.00M | Beam Therapeutics |
| 1-Year Return | 4.73% | -16.36% | Beam Therapeutics |
| Price-to-Sales Ratio (TTM) | 43.22 | 9.06 | Vertex |
| Enterprise Value | $1.54B | $98.55B | Vertex |
| EV/Revenue Ratio | 25.47 | 8.63 | Vertex |
| Gross Profit Margin (TTM) | N/A | 86.25% | N/A |
| Revenue per Share (TTM) | $1 | $44 | Vertex |
| Earnings per Share (Diluted) | $-4.50 | $14.06 | Vertex |
| Beta (Stock Volatility) | 2.25 | 0.43 | Vertex |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Beam Therapeutics vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Beam Therapeutics | 0.54% | 8.28% | 29.84% | 34.98% | 69.22% | 4.82% |
| Vertex | -0.10% | 1.92% | 1.94% | -12.30% | -15.10% | -0.70% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Beam Therapeutics | 4.73% | -43.06% | -20.61% | 25.56% | 25.56% | 25.56% |
| Vertex | -16.36% | 37.41% | 84.75% | 252.43% | 1,018.23% | 1,674.89% |
News Based Sentiment: Beam Therapeutics vs Vertex
Beam Therapeutics
News based Sentiment: MIXED
October saw a complex interplay of events for Beam Therapeutics, including notable insider sales alongside positive stock performance and continued analyst support. The conflicting signals create a mixed investment narrative, making it a significant month for the company's outlook.
Vertex
News based Sentiment: MIXED
October presented a mixed bag for Vertex, with a major FDA approval and positive financial results offset by a failed clinical trial and increased operating expenses. The strategic pipeline advancements and strong financial position suggest continued growth potential, but investors should monitor the impact of the trial setback and expense increases.
Performance & Financial Health Analysis: Beam Therapeutics vs Vertex
| Metric | BEAM | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $2.62B | $103.40B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 1,945,830 | 1,835,420 |
| 90 Day Avg. Volume | 2,688,497 | 1,652,450 |
| Last Close | $25.89 | $402.90 |
| 52 Week Range | $13.52 - $35.25 | $362.50 - $519.88 |
| % from 52W High | -26.55% | -22.50% |
| All-Time High | $138.52 (Jun 28, 2021) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -81.31% | -22.50% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.28% | 0.12% |
| Quarterly Earnings Growth | -0.28% | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.32% |
| Operating Margin (TTM) | -14.19% | 0.39% |
| Return on Equity (TTM) | -0.42% | 0.23% |
| Debt to Equity (MRQ) | 14.79 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $10.70 | $67.02 |
| Cash per Share (MRQ) | $11.71 | $24.90 |
| Operating Cash Flow (TTM) | $-344,824,000 | $3.85B |
| Levered Free Cash Flow (TTM) | $-164,037,248 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Beam Therapeutics vs Vertex
| Metric | BEAM | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -5.62 | 28.68 |
| Forward P/E | -5.40 | 21.49 |
| PEG Ratio | 0.57 | -0.22 |
| Price to Sales (TTM) | 43.22 | 9.06 |
| Price to Book (MRQ) | 2.41 | 6.02 |
| Market Capitalization | ||
| Market Capitalization | $2.62B | $103.40B |
| Enterprise Value | $1.54B | $98.55B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 25.47 | 8.63 |
| Enterprise to EBITDA | -3.62 | 20.53 |
| Risk & Other Metrics | ||
| Beta | 2.25 | 0.43 |
| Book Value per Share (MRQ) | $10.70 | $67.02 |
Financial Statements Comparison: Beam Therapeutics vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BEAM | VRTX |
|---|---|---|
| Revenue/Sales | $7.47M | $2.96B |
| Cost of Goods Sold | N/A | $407.50M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $98.82M | $978.40M |
| Operating Income (EBIT) | $-119.29M | $1.15B |
| EBITDA | $-113.91M | $1.34B |
| Pre-Tax Income | $-109.27M | $1.28B |
| Income Tax | N/A | $250.10M |
| Net Income (Profit) | $-109.27M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BEAM | VRTX |
|---|---|---|
| Cash & Equivalents | $527.91M | $4.67B |
| Total Current Assets | $1.25B | $10.01B |
| Total Current Liabilities | $141.55M | $3.78B |
| Long-Term Debt | $144.92M | $1.65B |
| Total Shareholders Equity | $1.12B | $16.50B |
| Retained Earnings | $-1.68B | $10.25B |
| Property, Plant & Equipment | $176.23M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BEAM | VRTX |
|---|---|---|
| Operating Cash Flow | $-81.45M | $404.90M |
| Capital Expenditures | $-3.07M | $-40.70M |
| Free Cash Flow | $-106.95M | $778.20M |
| Debt Repayment | $0 | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | BEAM | VRTX |
|---|---|---|
| Shares Short | 25.50M | 4.05M |
| Short Ratio | 8.98 | 2.83 |
| Short % of Float | 0.28% | 0.02% |
| Average Daily Volume (10 Day) | 1,945,830 | 1,835,420 |
| Average Daily Volume (90 Day) | 2,688,497 | 1,652,450 |
| Shares Outstanding | 83.63M | 256.94M |
| Float Shares | 87.02M | 255.58M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 1.05% | 0.98% |
Dividend Analysis & Yield Comparison: Beam Therapeutics vs Vertex
| Metric | BEAM | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |